Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Levamisole/5-fluorouracil for colon cancer

Executive Summary

Drug combo has been shown to substantially reduce cancer recurrence rates, delay onset of tumor relapse and improve survival rates for patients following surgical treatment, according to study of 408 patients released by NCI Oct. 2. Treatment IND for combo was approved in May. 48% of patients treated with combo were alive five years after therapy compared to 37% who received no post-operative treatment. Study's principal investigator concluded that "the option of therapy with levamisole and 5-FU should be offered to almost all patients who have surgical treatment for high-risk, stage C [Duke's] colon cancer".
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS016356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel